Literature DB >> 11920569

The tyrosine kinase Lyn is required for B cell development beyond the T1 stage in the spleen: rescue by over-expression of Bcl-2.

Josephine Meade1, Claire Fernandez, Martin Turner.   

Abstract

We have analyzed the effects of deficiency in the tyrosine kinase Lyn on B cell development using transgenic mice that express a B cell antigen receptor (BCR) of defined specificity (3-83,anti-H-2K(k or b)). In the absence of Lyn, immature B cells are abundant in the bone marrow and spleen up until the T1 stage (IgM(hi) IgD(-) CD21(-)CD23(-)), after which B cell development is severely impaired. The small number of mature B cells that do develop in Lyn-deficient mice express normal levels of the transgenic BCR and lack expression of CD80 and CD86, suggesting they are not activated. In Lyn-deficient animals the presence of a Bcl-2 transgene leads to a dramatic increase in B cell numbers and restores T2 stage (IgM(hi) IgD(hi) CD21(hi) CD23(int)) and mature populations. In 3-83 lyn-/- Bcl-2 Tg mice, a population of lambda-positive cells that also express the 383 idiotype is evident, suggesting that in the absence of lyn isotype exclusion by the transgenic BCR is less efficient. The results indicate that Lyn plays a positive role in the selection and survival of mature B cells in addition to its previously documented negative role in tolerance and B cell activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920569     DOI: 10.1002/1521-4141(200204)32:4<1029::AID-IMMU1029>3.0.CO;2-M

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  CD45: all is not yet crystal clear.

Authors:  Nick Holmes
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

2.  Lyn kinase promotes erythroblast expansion and late-stage development.

Authors:  Vinit G Karur; Clifford A Lowell; Peter Besmer; Valter Agosti; Don M Wojchowski
Journal:  Blood       Date:  2006-05-16       Impact factor: 22.113

3.  The development of mature B lymphocytes requires the combined function of CD19 and the p110δ subunit of PI3K.

Authors:  Dorottya Kövesdi; Sarah E Bell; Martin Turner
Journal:  Self Nonself       Date:  2010-03-11

4.  Lyn deficiency affects B-cell maturation as well as survival.

Authors:  Gitit Shahaf; Andrew J Gross; Michal Sternberg-Simon; Deborah Kaplan; Anthony L DeFranco; Ramit Mehr
Journal:  Eur J Immunol       Date:  2011-12-14       Impact factor: 5.532

Review 5.  Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Authors:  Alexey V Danilov
Journal:  Clin Ther       Date:  2013-09       Impact factor: 3.393

6.  Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.

Authors:  Jamie L Dargart; Kamonwan Fish; Leo I Gordon; Richard Longnecker; Osman Cen
Journal:  Antiviral Res       Date:  2012-05-16       Impact factor: 5.970

7.  Elevated BCR signaling and decreased survival of Lyn-deficient transitional and follicular B cells.

Authors:  Andrew J Gross; Irina Proekt; Anthony L DeFranco
Journal:  Eur J Immunol       Date:  2011-11-10       Impact factor: 5.532

8.  Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn.

Authors:  Mark Rovedo; Richard Longnecker
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

9.  A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function.

Authors:  Rina Barouch-Bentov; Jianwei Che; Christian C Lee; Yating Yang; Ann Herman; Yong Jia; Anastasia Velentza; James Watson; Luise Sternberg; Sunjun Kim; Niusha Ziaee; Andrew Miller; Carie Jackson; Manabu Fujimoto; Mike Young; Serge Batalov; Yi Liu; Markus Warmuth; Tim Wiltshire; Michael P Cooke; Karsten Sauer
Journal:  Mol Cell       Date:  2009-01-16       Impact factor: 17.970

10.  B cell-specific loss of Lyn kinase leads to autoimmunity.

Authors:  Chrystelle Lamagna; Yongmei Hu; Anthony L DeFranco; Clifford A Lowell
Journal:  J Immunol       Date:  2013-12-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.